Telomeye is a biotechnology company developing non-invasive treatments for corneal diseases like Fuchs Endothelial Corneal Dystrophy (FECD). The company's product, TAED017, leverages Nobel Prize-winning science related to telomere biology to address vision restoration. This work aims to preserve and enhance vision for patients suffering from CEC degeneration.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related ophthalmologic disorders, such as macular degeneration and cataracts, significantly impair vision and diminish quality of life as individuals age. Current treatments often provide limited efficacy or address only the symptoms, failing to target the underlying biological mechanisms driving disease progression. This unmet need leaves a substantial portion of the aging population vulnerable to vision loss and its associated burdens.
Solution
TelomEye Pharmaceuticals is developing targeted therapies that leverage telomere biology to prevent and treat age-related ophthalmologic disorders, specifically macular degeneration and cataracts. Their approach focuses on precise biological interventions designed to address the root causes of these conditions at the cellular level. By modulating telomere function, TelomEye aims to enhance visual acuity and slow the progression of these debilitating diseases, offering a more effective and sustainable solution for patients.
Target Audience
The primary target audience includes individuals at risk of or diagnosed with age-related macular degeneration and cataracts, as well as ophthalmologists and other eye care professionals seeking advanced therapeutic options.
Features
- Targeted drug candidates designed to modulate telomere length and function in retinal cells
- Therapeutic interventions aimed at preventing cellular senescence and oxidative stress in the eye
- Preclinical studies demonstrating improved visual function and reduced disease markers in animal models
- Novel drug delivery systems for targeted administration to the affected tissues in the eye